AR113850A1 - Antagonistas de ildr2 y combinaciones de los mismos - Google Patents

Antagonistas de ildr2 y combinaciones de los mismos

Info

Publication number
AR113850A1
AR113850A1 ARP180103490A ARP180103490A AR113850A1 AR 113850 A1 AR113850 A1 AR 113850A1 AR P180103490 A ARP180103490 A AR P180103490A AR P180103490 A ARP180103490 A AR P180103490A AR 113850 A1 AR113850 A1 AR 113850A1
Authority
AR
Argentina
Prior art keywords
ildr2
seq
combinations
same
antagonists
Prior art date
Application number
ARP180103490A
Other languages
English (en)
Inventor
Ilan Vaknin
Ph D Levy Ofer Levy
John Hunter
D Pow Andrew Ph
Spencer Liang
Htter Julia Dr
Gritzan Uwe Dr
Rse Lars Dr
Original Assignee
Bayer Pharma AG
Bayer Ag
Compugen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG, Bayer Ag, Compugen Ltd filed Critical Bayer Pharma AG
Publication of AR113850A1 publication Critical patent/AR113850A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Reivindicación 1: Una combinación farmacéutica, caracterizada porque comprende un antagonista de ILDR2 más, opcionalmente, uno o más compuestos terapéuticamente activos adicionales. Reivindicación 7: Un anticuerpo anti-ILDR2, o un fragmento o un derivado del mismo o un formato de anticuerpo modificado, todos los cuales tienen propiedades de unión a ILDR2, caracterizado porque comprende por lo menos las 3 secuencias de CDR de la cadena liviana: SEQ ID Nº 4 CDR1 LC SEQ ID Nº 5 CDR2 LC SEQ ID Nº 6 CDR3 LC.
ARP180103490A 2017-11-30 2018-11-28 Antagonistas de ildr2 y combinaciones de los mismos AR113850A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762592913P 2017-11-30 2017-11-30

Publications (1)

Publication Number Publication Date
AR113850A1 true AR113850A1 (es) 2020-06-17

Family

ID=64559680

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180103490A AR113850A1 (es) 2017-11-30 2018-11-28 Antagonistas de ildr2 y combinaciones de los mismos

Country Status (15)

Country Link
US (1) US11655297B2 (es)
EP (1) EP3717007A1 (es)
JP (1) JP7350740B2 (es)
KR (1) KR20200096223A (es)
CN (1) CN111655287A (es)
AR (1) AR113850A1 (es)
AU (1) AU2018376231A1 (es)
BR (1) BR112020010767A2 (es)
CA (1) CA3083675A1 (es)
IL (1) IL274751A (es)
MX (1) MX2020005483A (es)
RU (1) RU2020121533A (es)
SG (1) SG11202003323TA (es)
TW (1) TW201934119A (es)
WO (1) WO2019105972A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20212271A1 (es) * 2019-04-11 2021-11-30 Bayer Ag Combinaciones de anticuerpos anti-ildr2 y antagonistas de pd-1
CN111558038B (zh) * 2020-05-27 2022-04-19 北京加美康联健康管理集团有限公司 一种用于癌症治疗的免疫检查点抑制剂
CN111574626B (zh) * 2020-05-27 2021-12-31 斯爱玲 一种ildr2抗体、其药物组合物及其用途
US10894812B1 (en) 2020-09-30 2021-01-19 Alpine Roads, Inc. Recombinant milk proteins
US10947552B1 (en) 2020-09-30 2021-03-16 Alpine Roads, Inc. Recombinant fusion proteins for producing milk proteins in plants
IL301396A (en) 2020-09-30 2023-05-01 Nobell Foods Inc Recombinant milk proteins and food compositions containing them

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
ZA200603619B (en) 2003-11-06 2008-10-29 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
MY146381A (en) * 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
DK2769729T3 (en) 2007-09-04 2019-04-23 Compugen Ltd POLYPEPTIDES AND POLYNUCLEOTIDES AND APPLICATIONS THEREOF AS A PHARMACEUTICAL OBJECTIVE FOR THE PRODUCTION OF MEDICINAL PRODUCTS AND BIOTECHNOLOGICAL PRODUCTS
EP3202415B1 (en) * 2010-06-30 2021-12-08 Compugen Ltd. Fusion protein comprising a c1orf32 polypeptide and one or more domains of an immunoglobulin heavy chain constant region for treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders.
AU2012277376B2 (en) * 2011-06-30 2016-11-24 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
US20170233473A1 (en) * 2014-05-27 2017-08-17 Compugen Ltd. C10rf32 antibodies, and uses thereof for treatment of cancer
IN2014KN00848A (es) * 2012-02-01 2015-10-02 Compugen Ltd
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
IL300540B1 (en) 2014-04-10 2024-04-01 Daiichi Sankyo Co Ltd Preparation method for drug conjugates - antibody against - HER3
KR20180054701A (ko) 2015-09-16 2018-05-24 아블렉시스, 엘엘씨 항-cd115 항체

Also Published As

Publication number Publication date
KR20200096223A (ko) 2020-08-11
US11655297B2 (en) 2023-05-23
JP2021504404A (ja) 2021-02-15
EP3717007A1 (en) 2020-10-07
RU2020121533A (ru) 2021-12-30
AU2018376231A1 (en) 2020-05-07
MX2020005483A (es) 2020-08-27
SG11202003323TA (en) 2020-05-28
BR112020010767A2 (pt) 2020-11-24
WO2019105972A1 (en) 2019-06-06
IL274751A (en) 2020-07-30
US20200369769A1 (en) 2020-11-26
CN111655287A (zh) 2020-09-11
CA3083675A1 (en) 2019-06-06
JP7350740B2 (ja) 2023-09-26
TW201934119A (zh) 2019-09-01

Similar Documents

Publication Publication Date Title
AR113850A1 (es) Antagonistas de ildr2 y combinaciones de los mismos
CY1123833T1 (el) Μεθοδοι προληψης καρδιαγγειακων συμβαντων σε δυσλιπιδαιμικους πληθυσμους υπολειπομενου κινδυνου
PT3476399T (pt) Anticorpo lag-3, fragmento de ligação a antigénio deste e aplicação farmacêutica deste
AR111630A1 (es) ANTICUERPOS ANTI-SIRPa
CY1122245T1 (el) Pd-1 αντισωμα, θραυσμα δεσμευσης αντιγονου αυτου, και ιατρικη εφαρμογη αυτου
EP3753951A4 (en) ANTI-B7-H4 ANTIBODIES, ANTIGEN-BINDING FRAGMENT THEREOF AND PHARMACEUTICAL USE THEREOF
UY37694A (es) Dominios de unión a antígeno humanizados y métodos de uso
MX2018005720A (es) Anticuerpos pd-l1, fragmento de union al antigeno del mismo, y aplicacion medica de ello.
AR117911A2 (es) Anticuerpo anti-158p1d7 o fragmento de unión a antígeno del mismo, conjugado fármaco-anticuerpo, composición farmacéutica y sus usos
EA201890325A1 (ru) Пептидные ингибиторы рецептора интерлейкина-23 и их применение для лечения воспалительных заболеваний
UY36194A (es) Anticuerpos anti-tau humanizados
PE20170912A1 (es) Conjugados de anticuerpo-farmaco
EA202090800A1 (ru) Новые анти-cd3-эпсилон антитела
CY1123275T1 (el) Μορια συνδεσης ειδικα για il-21 και χρησεις αυτων
AR096601A1 (es) Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
ES2670621T3 (es) Anticuerpos que se unen a OX40 y sus usos
CO6410312A2 (es) Moléculas de anticuerpo que tienen especificidad por humano ox40
PE20091193A1 (es) Proteinas humanas de union a antigenos del gm-csf
EA201792300A1 (ru) Комбинации иммуноконъюгата к cd37 и антитела к cd20
CY1121158T1 (el) Αντισωμα ικανο να αναγνωριζει ειδικα υποδοχεα τρανσφερρινης
AR105267A1 (es) Anticuerpos de unión a tau
AR108717A1 (es) Anticuerpos antifactor de la coagulación xi
PE20230381A1 (es) Proteina de union a rgma
EP3922647A4 (en) ANTI-PD-1 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND PHARMACEUTICAL USE THEREOF
SG11202103670XA (en) Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex